Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
Verastem advances its experimental KRAS inhibitor to Phase III following positive early data and a major funding round.
6 trends tracked about this subject — the full history, oldest to newest below.
Verastem advances its experimental KRAS inhibitor to Phase III following positive early data and a major funding round.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AstraZeneca reports positive Phase III trial results for tozorakimab, a drug targeting COPD exacerbations.
Analysts are closely monitoring the impact of intismeran following a landmark Phase III clinical trial victory in the cancer vaccine sector.
Silence Therapeutics advances its gene-silencing drug divesiran toward Phase III following mid-stage trial success in polycythemia vera.